Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8040912 | 1.00 | CTSL (0.40) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL13318745 | 1.00 | CTSL (0.40) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL30574382 | 0.93 | CTSL (0.37) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL10395496 | 0.89 | ACACB (0.37) | CTSLPDE4DACACBL3MBTL1CYP19A1 | |
| SCHEMBL8028895 | 0.88 | L3MBTL1 (0.40) | CTSLPDE4DACACBPDE4APDE4B | |
| SCHEMBL23819043 | 0.85 | CTSL (0.38) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL31461598 | 0.85 | CTSL (0.38) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL23819181 | 0.85 | CTSL (0.38) | CTSLPDE4DGPR119ACACBPDE4A | |
| Hydrochloric Acid SCHEMBL30338425 | 0.84 | CTSL (0.38) | CTSLPDE4DGPR119ACACBPDE4A | |
| SCHEMBL18958971 | 0.84 | CYP19A1 (0.31) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332751-A1 | ANTIVIRAL PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-10-20 | — | — | US | claimed |
| EP-4028019-A1 | ANTIVIRAL PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF | The Scripps Research Institute (US) | 2022-07-20 | — | — | EP | claimed |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12187758-B2 | Compounds and methods for treating disease | ROME THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024188302-A1 | NUCLEOSIDE ANALOGUE TARGETING TELOMERASE AND USE THEREOF | 上海华汇拓医药科技有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4121437-A1 | PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115605493-A | Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same | 吉利德科学公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019289-A2 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CTSL 4211/4885PDE4D 4327/4885GPR119 3688/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CTSL 4211/4885PDE4D 4327/4885GPR119 3688/4885 |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | CTSL 21/4885PDE4D 1478/4885GPR119 3392/4885 |
| US-20220332751-A1 | ANTIVIRAL PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADA, PNP, ADAR | CTSL 454/4885PDE4D 90/4885GPR119 859/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | CTSL 17/4885PDE4D 2112/4885GPR119 3254/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | CTSL 18/4885PDE4D 2202/4885GPR119 3433/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | CTSL 51/4885PDE4D 1784/4885GPR119 2942/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | CTSL 683/4885PDE4D 420/4885GPR119 38/4885 |
| US-20250145654-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | CTSL 4211/4885PDE4D 4327/4885GPR119 3688/4885 |
| US-12187758-B2 | Compounds and methods for treating disease | EHMT1, POLRMT, RNASE1 | CTSL 4211/4885PDE4D 4327/4885GPR119 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.